← Eichor
Condition: Low Grade Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Low Grade Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630Epcoritamab and Rituximab for First-line Follicular Lymphoma
Phase 2 · 6 location(s) · Reid Merryman, MD · NCT05783609Italian Observational Study on CAR-T Therapy for Lymphoma
Phase N/A · 1 location(s) · Paolo Corradini · NCT06339255Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma
Phase N/A · 20 location(s) · Fondazione Italiana Linfomi - ETS · NCT05524298A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Se
Phase 1 · 4 location(s) · Lomond Therapeutics Holdings, Inc. · NCT0670889764Cu-LLP2A for Imaging Hematologic Malignancies
EARLY_Phase 1 · 1 location(s) · Washington University School of Medicine · NCT06636175Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgk
Phase 2 · 1 location(s) · Emory University · NCT04883437Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Phase 2 · 1 location(s) · University of Washington · NCT06442475NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Phase 2/Phase 3 · 4 location(s) · Health Institutes of Turkey · NCT07502118
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.